Rheumatoid Arthritis Disease Activity and Adverse Events in Patients Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of ORAL Surveillance
Ther Adv Musculoskelet Dis. 2023;15:1759720X231201047 doi: 10.1177/1759720X231201047
Post hoc analysis of ORAL Surveillance data highlights that active disease in RA leads to higher risk of adverse medical events, regardless of medication used.
People with RA and high disease activity are at a higher risk of adverse events, compared to those with LDA. Current therapeutics with different mechanisms of action increasingly enables attainment LDA, which may mitigate the risk of AEs caused by higher disease activity.
To investigate this hypothesis, Karpouzas, et al. used data from ORAL Surveillance to assess the relationships between RA disease activity and AEs of interest in patients treated with tofacitinib or TNFi.
Keywords:
